Fermenta Biotech Ltd Announces Unaudited Financial Results for Quarter Ended June 30, 2026
Fermenta Biotech Ltd has announced its unaudited financial results and a Limited Review Report for the quarter ended June 30, 2026, covering both standalone and consolidated performance. The Board of Directors approved the results, which detail operational performance across various segments and divisions.The company reported strong revenue generation and profitability in both individual company and group operations during the period. These results have been reviewed by independent statutory auditors.
Financial Performance Snapshot (Quarter Ended June 30, 2026)
Fermenta Biotech Ltd’s standalone performance saw a Total Income of 11,673.59 lakhs. The company recorded total expenses amounting to 9,659.01 lakhs, leading to a Profit before tax of 2,014.58 lakhs. After accounting for the total tax expense of 516.00 lakhs, the Profit after tax (PAT) was reported at 1,498.58 lakhs.On a consolidated basis, Total Income stood at 12,619.50 lakhs. Group expenses totaled 10,950.88 lakhs, resulting in a Profit before tax of 1,713.85 lakhs for the quarter. The reported Net Profit after tax was 7,025.43 lakhs.
A detailed comparison of key financial metrics across both standalone and consolidated results is presented below:
| Metric | Standalone (Q ended June 30, 2026) | Consolidated (Q ended June 30, 2026) |
|---|---|---|
| Total Income | 11,673.59 lakhs | 12,619.50 lakhs |
| Cost of Materials Consumed | 4,485.76 lakhs | 3,713.66 lakhs |
| Total Expenses (to date) | 9,659.01 lakhs | 10,950.88 lakhs |
| Profit before Tax | 2,014.58 lakhs | 1,713.85 lakhs |
| Net Profit after Tax | 1,498.58 lakhs | 7,025.43 lakhs |
Operational and Segment Highlights
Fermenta Biotech Ltd’s operations span multiple segments including Bulk drugs/chemicals, Property, and Unallocated areas. The performance of the Bulk drugs/chemicals segment saw revenue reach 11,341.96 lakhs in the standalone results for the quarter.Key operational updates include:
- Stock Options: During the quarter, the company granted 3,95,400 employee stock options to eligible employees under "The Fermenta Biotech Limited - Employee Stock Option Scheme 2025."
- Inventory Provision Reversal: The company reversed a provision of 7,205.00 lakhs relating to semi-finished inventory provided for in the earlier year towards animal feed production for the quarter ended June 30, 2026.
Segment Performance Summary (Standalone)
The following table outlines segment performance data as reported by the company:| Segment | Revenue from Operations (Q) | Total Profit before tax and finance cost (Q) |
|---|---|---|
| Bulk drugs/chemicals | 11,341.96 lakhs | 2,129.38 lakhs |
| Property | 199.36 lakhs | 6.84 lakhs |
| Unallocated (Net) | 132.27 lakhs | 132.27 lakhs |
Fermenta Biotech Ltd confirmed that the results are prepared in accordance with Indian Accounting Standards and that the figures for the previous periods have been regrouped or reclassified where necessary to conform to the current period classification.
FERMENTA Stock Price Movement
As of 2:46 PM, shares of Fermenta Biotech Limited are shedding 15.17% in live trading, with the stock currently dipping to ₹464.85. The equity has seen heavy activity so far, recording a volume of 336,186 shares in the market.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.